Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- Exploring Exhaled Breath as a New Platform for Gut Microbiome-Based Diagnostics (HCP Live)
- The Medical Futurist’s 100 Digital Health And AI Companies Of 2026 (The Medical Futurist)
- MedPAC signals need to bolster Medicare physician payments (American Medical Association)
- Want to Reach Nirvana? Try a Colonoscopy. (The New York Times)
- Aidoc Secures FDA Clearance for Healthcare’s First Comprehensive Foundation Model AI (AIdoc)
- NYU Langone Health Announces Gastrointestinal Cancer & Translational Research Leader Dr. Anirban Maitra as New Director of Perlmutter Cancer Center (NYU Langone Health)
- Bringing biomarker testing within reach: CLEAR for CRC to empower patients from day one (Colorectal Cancer Alliance)
- GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test (GRAIL)
